{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-23-032041","form_type":"8-K","ticker":"BCTX","cik":"0001610820","company_name":"BriaCell Therapeutics Corp.","filed_at":"2023-09-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:34.547926+00:00","generated_at":"2026-06-10T22:11:49.637939+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"BriaCell Phase 2 breast cancer study shows 13.5-month median overall survival vs 6.7-9.8 months literature","bullets":["Median overall survival 13.5 months in BriaCell's Phase 2 study vs 6.7-9.8 months for similar advanced metastatic breast cancer patients in literature.","21 of 29 patients treated since 2022 remain alive, suggesting strong survival benefit with combination regimen.","No dose limiting toxicities reported; Phase 2 study fully enrolled with 46 heavily pre-treated patients (average 5 prior treatments).","Combination regimen of Bria-IMT™ with checkpoint inhibitors (pembrolizumab or retifanlimab-dlwr) shows tolerability and efficacy.","Data supports upcoming pivotal study in advanced breast cancer."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-23-032041","json":"https://secwatch.observer/filing/0001493152-23-032041.json","markdown":"https://secwatch.observer/filing/0001493152-23-032041.md","text":"https://secwatch.observer/filing/0001493152-23-032041.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1610820/000149315223032041/0001493152-23-032041-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1610820/000149315223032041/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-10T22:11:49.637939+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}